Teva and Daiichi Sankyo named and shamed for UK code breaches
Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) and Japanese drugmaker Daiichi Sankyo (TYO: 4568) have been called out for breaches of the Association of the British Pharmaceutical Industry (ABPI) Code of Practice.
The Prescription Medicines Code of Practice Authority (PMCPA), which operates the code of practice, has said that the companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry.
Teva was found to be in breach of clauses of the 2019 code for failing to include the black triangle for the migraine drug Ajovy (fremanezumab) in an article that the company was seen to be responsible for and was promotional, which was compounded by a failure to include an adverse event reporting statement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze